Cellectis (NASDAQ:CLLS) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS) in a research note issued to investors on Friday. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Barclays decreased their price objective on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th.

Cellectis Price Performance

CLLS stock opened at $2.10 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78. The firm has a market capitalization of $116.72 million, a P/E ratio of -1.64 and a beta of 3.10. The business’s 50-day moving average is $1.95 and its two-hundred day moving average is $2.18. Cellectis has a 1 year low of $1.70 and a 1 year high of $3.77.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The business had revenue of $18.05 million during the quarter, compared to analysts’ expectations of $5.00 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. During the same quarter in the previous year, the company posted ($0.31) EPS. Analysts anticipate that Cellectis will post -0.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cellectis

Hedge funds and other institutional investors have recently bought and sold shares of the company. XTX Topco Ltd purchased a new position in Cellectis during the second quarter worth $29,000. First Affirmative Financial Network acquired a new position in shares of Cellectis during the third quarter worth about $45,000. Principal Financial Group Inc. lifted its stake in shares of Cellectis by 2.9% during the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after purchasing an additional 12,467 shares in the last quarter. Finally, Long Focus Capital Management LLC lifted its stake in shares of Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after acquiring an additional 130,000 shares in the last quarter. 63.90% of the stock is owned by institutional investors and hedge funds.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.